Navigation Links
More Evidence Virus Plays Role in Chronic Fatigue Syndrome
Date:8/24/2010

By Jenifer Goodwin
HealthDay Reporter

MONDAY, Aug. 23 (HealthDay News) -- Another study has found evidence that a mouse virus may play a role in chronic fatigue syndrome, a poorly understood disorder that causes incapacitating exhaustion and malaise.

Using blood samples collected in the mid-1990s from chronic fatigue sufferers from the New England area, researchers found evidence of gene sequences for murine leukemia virus (MLV)-related virus in the blood of 32 of 37 patients, or 86.5 percent.

Evidence of the virus was detected in only three of 44 healthy controls, or 6.8 percent of people who did not have chronic fatigue syndrome, the researchers noted.

The team also did genetic testing on fresh blood samples from eight of the chronic fatigue patients and found evidence of MLV in seven of them.

The study, published in the Aug. 23-27 online edition of the Proceedings of the National Academy of Sciences, was conducted by researchers from the U.S. Food and Drug Administration, Brigham and Women's Hospital in Boston, and the U.S. National Institutes of Health.

About one million people in the United States have chronic fatigue syndrome, according to the Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) Association of America. Symptoms include debilitating exhaustion that lasts for months and is not alleviated by sleep and often made worse by physical activity.

People with chronic fatigue can also experience joint aches and muscle pain, headaches, enlarged lymph nodes and sore throat. At the same time, many have to battle with the disbelief (from some quarters) that CFS is a "real" disease.

The saga of MLV-related viruses and chronic fatigue syndrome began last October, when a different team of researchers reported in the journal Science that they had found a mouse virus called xenotropic murine leukemia virus-related virus, or XMRV, in the blood of 68 of 101 patients with chronic fatigue syndrome, but in only eight of 218 healthy patients.

Previously, the same team had reported that they found the virus in some prostate cancer patients.

After decades of confusion about the illness, finally, it seemed, researchers were honing in on a biological cause for the mysterious condition, said Kim McCleary, president and CEO of the CFIDS Association of America.

Yet four subsequent teams of researchers failed to find a similar link, leaving patients even more confused. So, the new findings are an important confirmation that an MLV-related virus may indeed play a role, McCleary said.

"This study is certainly vindication for the disbelief that has been so pervasive over the past 20 years," McCleary said. "But as so often happens with science, every answer begs more questions."

Experts don't know if the presence of MLV-related virus gene sequences reflect an underlying immune disorder, if the virus alters the immune system and allows in other viruses, or if it's the virus itself that is making people sick, McCleary said.

Also unexplained is why some healthy people have MLV-related virus in their blood but don't fall ill, said Dr. Celia Witten, director of the Office of Cellular, Tissue and Gene Therapies at the U.S. Food and Drug Administration.

And the current findings differ from the previous research in one important respect. While the findings reported in Science identified xenotropic murine leukemia virus-related virus (XMRV) in the blood of those with chronic fatigue, the current study did not did find XMRV.

Instead, researchers found gene sequences for polytropic mouse endogenous retroviruses, which are in the same family of retroviruses but is not identical to XMRV, explained lead study author Dr. Shyh-Ching Lo, director of the Tissue Safety Laboratory Program at the U.S. Food and Drug Administration.

A retrovirus is a specific kind of virus that can integrate itself into the host genome. Researchers don't know how it's transmitted.

"Our study very much supports the earlier findings that MLV-related viruses are found in the chronic fatigue syndrome patients, although the virus sequence we identified is not the same as XMRV and is a much more heterogenous group," Lo said.

XMRV is a newly identified form of the MLV-related virus that has been shown to infect human cells but not mouse cells, Witten said, while polytropic MLV-related virus can infect both human cells and mouse cells.

"Difference in sequences can cause difference in the virus' function and pathology," Witten said. "But exactly how pathogenic they are in people, how they cause infection or even whether they can all remains to be seen."

More information

The U.S. Centers for Disease Control and Prevention has more on chronic fatigue.

SOURCES: Shyh-Ching Lo, M.D., Ph.D., director, Tissue Safety Laboratory Program, Division of Cellular and Gene Therapies and Division of Human Tissues, Office of Cellular, Tissue and Gene Therapies, U.S. Food and Drug Administration, Bethesda, Md.; Celia Witten, M.D., Ph.D., director, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Md.; Kim McCleary, president and CEO, CFIDS Association of America, Charlotte, N.C.; Aug. 23, 2010, PNAS, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
2. Evidence-based care and outcomes improve at Get With The Guidelines-Stroke hospitals
3. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
4. More Evidence That Swings in Blood Pressure Raise Stroke Risk
5. Cellular pathway could provide evidence of how cancer and obesity are linked
6. Palladians Distinguished Clinicians Present at APTAs National CSM Convention in San Diego on Evidenced Informed Management of Chronic Low Back Pain Without Surgery
7. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
8. Elseviers Journal of Evidence-Based Dental Practice celebrates 10th year with special issue
9. Evidence-based medicine theory can be applied to frequent flying says US professor
10. No Evidence That Lithium Helps in ALS
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Evidence Virus Plays Role in Chronic Fatigue Syndrome
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, ... Rod has been at the forefront of Gardant since it was founded in 1999. ... overseen the opening of more than 40 new senior living communities. With his leadership, ...
(Date:4/24/2017)... ... 2017 , ... Donna Parker, L. Ac. reads all sorts of books on ... to be very practical. She wanted to write a guide/workbook that would give readers ... It prompted her in writing “ A Clear Path to a Vibrant Life : ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration ... Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel located ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a ... process rendered in my Art and Music. These are created as Metaphysical Transformations where ... boundary of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer brings ... of Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is responsible ... and strategic planning for the company. Recognized industry-wide as a healthcare innovator, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
Breaking Medicine Technology: